Certa Therapeutics
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
31 Queen St L 9, Melbourne, Victoria, 30...Website
www.certatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Certa Therapeutics
Certa Therapeutics is focused on developing innovative precision therapies for patients suffering from inflammatory and fibrotic diseases. The company aims to be a leading anti-fibrotic organization by creating targeted therapeutics for serious conditions such as scleroderma, chronic kidney disease, diabetic nephropathy, and focal segmental glomerulosclerosis. Their mission is to pioneer breakthroughs in the treatment of these life-threatening diseases. Certa Therapeutics serves patients in need of advanced medical solutions for fibrotic diseases.Explore more
Certa Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Certa Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Certa Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Certa Therapeutics has new funding data
Click to see if Certa Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Certa Therapeutics launches new products
Check out if Certa Therapeutics is spiking on competitors!
Earning: See what the market has to say on Certa Therapeutics recently announced quarterly report
Check if Certa Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Certa Therapeutics
Recommended Actions
Find VP level buyers at Certa Therapeutics
Find 3 more new buyers
Compare Similar Companies to Certa Therapeutics
Compare insights from companies similar to Certa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Certa Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Certa Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Certa Therapeutics.
Certa Therapeutics Tech Stack
A closer look at the technologies used by Certa Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Mergers & Acquisitions (M&A)
Certa Therapeutics News & Media
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
MELBOURNE, Australia, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces that its lead candidate FT011 has been granted the International Non-Proprietary Name (INN) of ‘asengeprast’ by the World Health Organisation (WHO). Commonly known as a generic name, an INN is a globally recognised, unique name for a pharmaceutical substance or active ingredient.Certa Therapeutics Receives EU Orphan Designation for FT011, a GPR68 Inhibitor Being Developed as an Anti-Fibrotic Treatment for Systemic Sclerosis
MELBOURNE, Australia, July 22, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) for its lead drug candidate, FT011, as a potential treatment of Systemic Sclerosis (SSc). Certa has previously also received ODD and Fast Track designation for FT011 as a potential treatment of SScCerta Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the Treatment of Systemic Sclerosis
MELBOURNE, Australia, Oct. 23, 2023 /PRNewswire/ -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical diseases orGround-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Certa Therapeutics
Sign Up For FreeTo access detailed company insights
Certa Therapeutics is focused on developing innovative precision therapies for patients suffering from inflammatory and fibrotic diseases. The company aims to be a leading anti-fibrotic organization by creating targeted therapeutics for serious conditions such as scleroderma, chronic kidney disease, diabetic nephropathy, and focal segmental glomeru... Read More
